Chugai Pharmaceutical Co. vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chugai Pharmaceutical Co., Ltd. (4519.JP)

Q3 202624 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

August 202624 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

Latest24 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.